Pr13.5 promoter for robust T-cell and antibody responses

Patent metadata

Field	Value
Publication number	US-9828414-B2
Application number	US-201314437939-A
Country	US
Kind code	B2
Filing date	Oct 28, 2013
Priority date	Oct 28, 2012
Publication date	Nov 28, 2017
Grant date	Nov 28, 2017

Abstract

The invention encompasses recombinant poxviruses, preferably modified Vaccinia Ankara (MVA) viruses, comprising a Pr13.5 promoter operably linked to a nucleotide sequence encoding an antigen and uses thereof. The invention is drawn to compositions and methods for the induction of strong CD8 T cell and antibody responses to a specific antigen(s) by administering one or more immunizations of the recombinant MVA to a mammal, preferably a human.

First claim

We claim:

1. A method of inducing a robust CD8 T cell response against a neoantigen in a human comprising administering one or more administrations of a recombinant modified Vaccinia Ankara (MVA) virus to the human;
wherein the recombinant MVA comprises a Pr13.5 promoter operably linked to a nucleotide sequence encoding the neoantigen,
wherein the Pr13.5 promoter comprises at least 2 copies of SEQ ID NO:1, and wherein the at least 2 copies of SEQ ID NO:1 are separated by 30-40 nucleotides.

2. The method of claim 1 , wherein the Pr13.5 promoter comprises SEQ ID NO:2.

3. A recombinant modified Vaccinia Ankara (MVA) virus comprising a Pr13.5 promoter operably linked to a nucleotide sequence encoding a neoantigen,
wherein the Pr13.5 promoter comprises at least 2 copies of SEQ ID NO:1, and wherein the at the at least 2 copies of SEQ ID NO:1 are separated by 30-40 nucleotides.

4. The recombinant MVA of claim 3 , wherein the Pr13.5 promoter comprises SEQ ID NO:2.

Assignees

• Bavarian Nordic As

Inventors

• Steigerwald Robin
• Brinkmann Kay

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K2039/572

  cytotoxic response · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N2830/60

  from viruses · CPC title

• A61K2039/5256

  expressing foreign proteins · CPC title